Drugs / Daclizumab
Daclizumab
also known as
Zenapax · BIIB019 · anti-TAC · DAC HYP · Daclizumab High Yield Process · daclizumab, zenapax · DZB · Zenapax (Daclizumab) · +1 more
Monoclonal antibody targets IL2RA via depletion
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed relapsing-remitting multiple sclerosis 2 milestones | |||||
| Filed | US (FDA) | ZINBRYTA | relapsing-remitting multiple sclerosis | 2015-04-29 | “FDA has accepted for review the companies’ Biologics License Application (BLA) requesting marketing approval of ZINBRYTA™” biogen.com ↗ |
| Filed | EU (EMA) | ZINBRYTA | relapsing-remitting multiple sclerosis | 2015-03-27 | “validated the companies’ Marketing Authorisation Application (MAA) for ZINBRYTA™ (daclizumab high-yield process) for the treatment of relapsing forms of multiple sclerosis (MS)” biogen.com ↗ |
| Withdrawn Indication not stated 4 milestones | |||||
| Withdrawn | EU (EMA) | Zinbryta | — | 2018-03-27 | europa.eu ↗ |
| Label expansion | US (FDA) | ZINBRYTA | — | 2017-05-26 | fda.gov ↗ |
| Approved | US (FDA) | ZINBRYTA | — | 2016-05-27 | fda.gov ↗ |
| Approved | EU (EMA) | Zenapax | — | 1999-02-26 | europa.eu ↗ |
Trials 47
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT01143441 | May 2010 → Aug 2017 | relapsing-remitting multiple sclerosis | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 1 | NCT00626015 | Mar 2007 → Feb 2013 | brain cancer | John Sampson | Completed | No outcome recorded |
| Phase 1 | NCT00080431 | Mar 2004 → Dec 2007 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00078689 | Mar 2004 → Jul 2008 | uveitis | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 1 | NCT00001526 | Jun 1996 → Sep 2007 | uveitis | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 1/26 trials · 1 missed | ||||||
| Phase 1/2 | NCT00141037 | Mar 2004 → Sep 2006 | kidney disorder | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
| Phase 1/2 | NCT00847106 | Mar 2004 → Oct 2005 | melanoma | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00284531 | Oct 2003 → May 2007 | — | Baylor College of Medicine | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00001941 | Dec 1999 → Feb 2011 | T-cell leukemia, human T-lymphotropic virus 1 infectious disease | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00050661 | Oct 1997 → Apr 2004 | psoriasis | Rockefeller University | Completed | No outcome recorded |
| Phase 1/2 | NCT00002681 | Jul 1995 → Sep 2003 | leukemia, lymphoma | Roger Williams Medical Center | Completed | No outcome recorded |
| Phase 219 trials · 1 met primary · 2 missed | ||||||
| Phase 2 | NCT01051349 | Mar 2010 → Aug 2016 | relapsing-remitting multiple sclerosis | Biogen | Completed | No outcome recorded |
| Phase 2 | NCT00390221 | Feb 2008 → May 2011 | relapsing-remitting multiple sclerosis | Biogen | Completed | Met primary |
| Phase 2 | NCT00326508 | May → Dec 2006 | uveitis | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 2 | NCT00130637 | Aug 2005 → May 2008 | anterior uveitis, iritis, juvenile idiopathic arthritis | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 2 | NCT00109161 | Apr 2005 → Oct 2006 | multiple sclerosis | PDL BioPharma, Inc. | Completed | Mixed |
| Phase 2 | NCT00100178 | May 2004 → Apr 2008 | type 1 diabetes mellitus | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | Missed primary |
| Phase 2 | NCT00072969 | Nov 2003 → Aug 2005 | myelodysplastic syndrome | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 2 | NCT00071838 | Oct 2003 → Oct 2007 | relapsing-remitting multiple sclerosis | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
| Phase 2 | NCT00070759 | Oct 2003 → Oct 2006 | uveitis | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 2 | NCT00064714 | Jul 2003 → Mar 2008 | diabetes mellitus | AstraZeneca | Completed | Missed primary |
| Phase 2 | NCT00073047 | Apr 2003 → Jul 2006 | ulcerative colitis | Facet Biotech | Completed | No outcome recorded |
| Phase 2 | NCT00049725 | Nov 2002 → Dec 2004 | thrombocytopenia | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 2 | NCT00693524 | Nov 2002 → Mar 2004 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT00043667 | Aug 2002 → Oct 2004 | uveitis | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 2 | NCT00040248 | Jun 2002 → May 2005 | granulomatosis with polyangiitis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00028288 | Sep 2001 → Dec 2003 | asthma | Facet Biotech | Completed | No outcome recorded |
| Phase 2 | NCT00006350 | Jan 2000 → Nov 2001 | leukemia, myelodysplastic syndrome, plasma cell neoplasm | University of Maryland, Baltimore | Completed | No outcome recorded |
| Phase 2 | NCT00001962 | Nov 1999 → Aug 2009 | Diamond-Blackfan anemia | National Heart, Lung, and Blood Institute (NHLBI) | Terminated | No outcome recorded |
| Phase 2 | NCT00001865 | Jul 1999 → Jun 2004 | Behcet disease, retinal disorder, uveitis | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00181142 | Oct 1999 → Dec 2004 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 36 trials · 1 missed | ||||||
| Phase 3 | NCT07689630 | May 2026 → May 2028 expected | acute graft versus host disease, hematopoietic and lymphoid cell neoplasm | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 3 | NCT02881567 | Apr 2017 → Sep 2018 | relapsing-remitting multiple sclerosis | Biogen | Terminated | No outcome recorded |
| Phase 3 | NCT00275509 | Jan 2007 → Jun 2010 | chronic renal failure syndrome | Johns Hopkins University | Completed | No outcome recorded |
| Phase 3 | NCT00296348 | Nov 2005 → Feb 2008 | — | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 3 | NCT00195273 | Nov 2004 → Jul 2008 | graft versus host disease | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | Missed primary |
| Phase 3 | NCT00053976 | Jan 2001 → Nov 2003 | acute graft versus host disease | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 49 trials · 1 met primary · 1 missed | ||||||
| Phase 4 | NCT00574470 | Jan 2006 → Nov 2007 | graft versus host disease | University of Iowa | Completed | No outcome recorded |
| Phase 4 | NCT00246129 | Oct 2005 → Jun 2011 | kidney failure | EMagnusson | Completed | Missed primary |
| Phase 4 | NCT02554955 | Feb 2004 → Dec 2007 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT02576145 | Apr 2003 → Jan 2006 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 4 | NCT00231764 | Nov 2002 → May 2006 | — | Ekberg, Henrik, M.D. | Completed | No outcome recorded |
| Phase 4 | NCT00685061 | Nov 2002 → Sep 2004 | — | University of Miami | Completed | No outcome recorded |
| Phase 4 | NCT00681343 | Sep 2002 → Oct 2006 | — | University of Miami | Completed | No outcome recorded |
| Phase 4 | NCT00048165 | Aug 1999 → Aug 2002 | — | Hoffmann-La Roche | Completed | Met primary |
| Phase 4 | NCT01418430 | — | adult T-cell leukemia/lymphoma | King's College Hospital NHS Trust | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00023231 | Feb 2001 → Aug 2004 | end stage renal failure | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Comparator or background therapy20 trials | ||||||
| Phase 1/2 | NCT00579527 Background | Dec 2005 → Dec 2011 | DiGeorge syndrome | Sumitomo Pharma Switzerland GmbH | Completed | No outcome recorded |
| Phase 1/2 | NCT00566813 Comparator | Nov 2004 → Jul 2010 | type 1 diabetes mellitus | University of Illinois at Chicago | Completed | No outcome recorded |
| Phase 1/2 | NCT00050648 Comparator | Oct 1997 → Sep 2004 | psoriasis | Rockefeller University | Completed | No outcome recorded |
| Phase 2 | NCT02694770 Comparator | Jul 2016 → Sep 2017 | acute graft versus host disease | AbGenomics B.V Taiwan Branch | Withdrawn | No outcome recorded |
| Phase 2 | NCT00790439 Background | Jul 2008 → Oct 2009 | type 1 diabetes mellitus | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT00468442 Background | Nov 2006 → Sep 2011 | type 1 diabetes mellitus | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 2 | NCT00434850 Background | Oct 2006 → Sep 2011 | type 1 diabetes mellitus | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00304954 Comparator | Feb 2006 → Jan 2010 | age-related macular degeneration, choroidal neovascularization | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 2 | NCT00295607 Comparator | Jun 2005 → Jun 2008 | hepatitis C virus infection | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT00446264 Background | May 2003 → Oct 2007 | hypoglycemia, type 1 diabetes mellitus | University Hospital, Lille | Completed | No outcome recorded |
| Phase 2 | NCT00014911 Background | Apr 2001 → Jun 2005 | type 1 diabetes mellitus | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT00468117 Background | Jan 2007 → Jul 2015 | type 1 diabetes mellitus | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT02686619 Background | Nov 2004 → Jan 2011 | — | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00682292 Comparator | May 2001 → Nov 2006 | — | University Hospital, Lille | Completed | No outcome recorded |
| Phase 4 | NCT01172418 Comparator | Feb 2006 → May 2010 | — | University of Miami | Completed | Missed primary |
| Phase 4 | NCT01046955 Comparator | Nov 2005 → Apr 2007 | end stage renal failure | University of Miami | Completed | No outcome recorded |
| Phase 4 | NCT00132691 Comparator | Sep 2005 → Dec 2010 | uveitis | JHSPH Center for Clinical Trials | Completed | No outcome recorded |
| Phase 4 | NCT00493194 Background | May 2005 → Jul 2007 | chronic renal failure syndrome, disease related to solid organ transplantation, renal fibrosis | University Hospital, Antwerp | Unknown | No outcome recorded |
| Phase 4 | NCT00363116 Comparator | Apr 1999 → Dec 2004 | acute transplant rejection | University of Cincinnati | Completed | No outcome recorded |
| — | NCT00859131 Comparator | Mar 2009 → Jul 2012 | end stage renal failure | Medical University of South Carolina | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 19
| Date | Issuer | Release |
|---|---|---|
| 2018-03-02 | Biogen | Regulatory Biogen and AbbVie Announce the Voluntary Worldwide Withdrawal of Marketing Authorizations for ZINBRYTA® (daclizumab) for Relapsing Multiple Sclerosis biogen.com ↗
Biogen (Nasdaq:BIIB) and AbbVie (NYSE:ABBV) today announced the voluntary worldwide withdrawal of ZINBRYTA for relapsing multiple sclerosis. |
| 2016-09-15 | Biogen | Results New Data Presented at ECTRIMS Reinforce Efficacy of ZINBRYTA™ (Daclizumab) and Support Long-Term Safety Profile biogen.com ↗
A new post-hoc analysis from the pivotal DECIDE study shows that a significantly greater number of people treated with ZINBRYTA TM (daclizumab) achieved no evidence of disease activity (NEDA) compared to those taking AVONEX ® (interferon beta-1a) intramuscular injection. |
| 2016-09-08 | Biogen | Results Biogen Demonstrates Commitment to Improving Patient Outcomes with Study on Burden of MS and New Clinical Data from Its Leading MS Portfolio biogen.com ↗
A new analysis from the pivotal DECIDE study that further supports the positive impact of ZINBRYTA on no evidence of disease activity (NEDA), and the first interim results from the ongoing EXTEND study, providing up to five years of efficacy and safety data. |
| 2016-07-05 | Biogen | Regulatory Biogen and AbbVie’s Once-Monthly ZINBRYTA™ (Daclizumab) Approved in European Union for Treatment of Multiple Sclerosis biogen.com ↗
The European Commission (EC) has granted marketing authorization for ZINBRYTA™ (daclizumab) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) announced today. |
| 2016-05-27 | AbbVie | Regulatory Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (daclizumab) for Multiple Sclerosis abbvie.com ↗
The U.S. Food and Drug Administration (FDA) approved ZINBRYTA™ (daclizumab), a new once-monthly, self-administered, subcutaneous treatment for relapsing forms of multiple sclerosis (RMS), Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) announced today. |
| 2016-05-27 | Biogen | Regulatory Biogen and AbbVie Receive FDA Approval of Once-Monthly ZINBRYTA™ (Daclizumab) for Multiple Sclerosis biogen.com ↗
The U.S. Food and Drug Administration (FDA) approved ZINBRYTA TM (daclizumab), a new once-monthly, self-administered, subcutaneous treatment for relapsing forms of multiple sclerosis (RMS), Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) announced today. |
| 2016-04-29 | Biogen | Regulatory Biogen and AbbVie Receive Positive Opinion from the CHMP on ZINBRYTA™ (Daclizumab) for Treatment of Multiple Sclerosis biogen.com ↗
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a marketing authorization for ZINBRYTA™ (daclizumab) intended for the treatment of relapsing forms of multiple sclerosis (RMS), Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) announced today. |
| 2016-04-20 | Biogen | Results Data Presented at AAN Highlight Impact of ZINBRYTA™ (Daclizumab HYP) on Cognitive Outcomes and the Reversibility of Its Targeted Mechanism of Action biogen.com ↗
New data presented today show that investigational therapy ZINBRYTA TM (daclizumab HYP) provided improvements on cognitive outcome measures in people living with relapsing forms of multiple sclerosis (RMS). |
| 2016-04-12 | Biogen | Results Biogen Data at 2016 AAN Annual Meeting Highlight Its Expansive Portfolio of MS Therapies That Meets Diverse Needs of Patients biogen.com ↗
ZINBRYTA Improved Cognitive Outcomes in Relapsing-Remitting Multiple Sclerosis with Daclizumab HYP in the Phase 3 DECIDE Study |
| 2015-10-08 | Biogen | Results Results from ZINBRYTA™ (Daclizumab High-Yield Process) Phase 3 DECIDE Study Highlighting Efficacy Compared to Interferon Beta-1a Published in the New England Journal of Medicine and Presented at ECTRIMS biogen.com ↗
Lead investigators on behalf of Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) presented these new findings today at the 31st Congress of the European Committee for Treatment and Research in MS (ECTRIMS) in Barcelona, Spain (7-10 October). |
| 2015-04-29 | Biogen | Regulatory FDA Accepts Biologics License Application For ZINBRYTA (Daclizumab High-Yield Process) For Treatment of MS biogen.com ↗
Today Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) announced that the U.S. Food and Drug Administration (FDA) has accepted for review the companies’ Biologics License Application (BLA) requesting marketing approval of ZINBRYTA™ (daclizumab high-yield process) for relapsing forms of multiple sclerosis (MS). |
| 2015-03-27 | Biogen | Regulatory European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA™ (Daclizumab High-Yield Process) for Treatment of MS biogen.com ↗
Today Biogen (NASDAQ: BIIB) and AbbVie (NYSE: ABBV) announced that the European Medicines Agency (EMA) has validated the companies’ Marketing Authorisation Application (MAA) for ZINBRYTA™ (daclizumab high-yield process) for the treatment of relapsing forms of multiple sclerosis (MS) in the European Union (EU). |
| 2014-09-12 | Biogen | Results Detailed Results from Biogen Idec and AbbVie’s Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High-Yield Process) biogen.com ↗ |
| 2014-06-16 | Biogen | Results Biogen Idec and AbbVie Announce Positive Top-Line Results from Phase 3 Study Investigating Daclizumab High-Yield Process in Multiple Sclerosis biogen.com ↗
Results showed that DAC HYP was superior on the study’s primary endpoint, demonstrating a statistically significant 45 percent reduction in annualized relapse rate (ARR) compared to IFN β-1a (p<0.0001). |
| 2014-04-14 | Biogen | Results Biogen Idec to Present New Clinical Data from Its Robust Neurology Portfolio at AAN Annual Meeting biogen.com ↗
Reduction in brain atrophy with extended daclizumab HYP treatment: Results of SELECT and the SELECT extension study |
| 2013-04-04 | Biogen | Results The Lancet Publishes SELECT Study Evaluating Efficacy and Safety of Daclizumab HYP in Multiple Sclerosis biogen.com ↗
In addition, results demonstrated that DAC HYP reduced multiple sclerosis (MS) brain lesions compared to placebo. |
| 2011-10-22 | Biogen | Results Biogen Idec and Abbott Present Positive Data for Daclizumab HYP from Select Phase 2B Trial at ECTRIMS/ACTRIMS biogen.com ↗
In addition to meeting the primary endpoint, both doses of DAC HYP met key secondary endpoints, including measures of magnetic resonance imaging (MRI). |
| 2011-08-09 | Biogen | Results Biogen Idec and Abbott Announce Positive Top-Line Results from the First Registrational Trial for Daclizumab HYP in Relapsing-Remitting Multiple Sclerosis biogen.com ↗
Findings showed that DAC HYP reduced the risk of sustained disability progression at one year by 57 percent in the 150 mg dose arm and by 43 percent in the 300 mg dose arm compared to placebo. |
| 2010-04-05 | Biogen | Results Biogen Idec Strengthens Position as a Leader in Neurology with 38 Data Presentations at 62nd Annual Meeting of the American Academy of Neurology biogen.com ↗
The second focuses on daclizumab’s effect on the balance of regulatory and activated T-cell (immune cell) numbers in people with MS ( Changes in Circulating Tregs Parallel Reductions in Activated T Cells During Daclizumab Treatment of MS – P04.193). |
All press releases naming this drug 21 releases
Evidence & citations 14 cited values
Every value below carries the sentence it was read from. 68 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | daclizumab | “Anti-CD25 monoclonal antibody, also described as daclizumab in the protocol, will be administered intravenously at 1 mg/kg on Day 0 and Day +4 after haploidentical...” NCT07689630 ↗67“A comparison will be made between two regimens which both include tacrolimus, one utilizing standard steroid administration and the second with daclizumab (MAB) avoiding...” NCT00295607 ↗ “combined regimen of mycophenolate mofetil and monoclonal anti-IL2R antibodies (daclizumab), in comparison with a standard steroid + tacrolimus double drug regimen” NCT00693524 ↗ “Daclizumab is an interleukin 2 receptor (IL-2) antagonist which is FDA approved as an immunosuppressive agent.” NCT00181142 ↗ “methotrexate, basiliximab, daclizumab, inolimomab, denileukin diftitox, alemtuzumab, ATG+ etanercept” NCT02694770 ↗ “150 mg of daclizumab high yield process (DAC HYP) administered subcutaneously (SC)” NCT01143441 ↗ “using daclizumab 1 mg/kg IV immediately pre-transplant” NCT00566813 ↗ “Biological: Daclizumab” NCT00468442 ↗ “daclizumab” NCT00132691 ↗ “daclizumab” NCT00132691 ↗ |
| Known as | anti-TAC | “This study compares the efficacy and analyzes the cellular effects of anti-TAC (Daclizumab) and Cyclosporine in the treatment of psoriasis vulgaris.” NCT00050648 ↗ |
| Known as | BIIB019 | “BIIB019 (Daclizumab High Yield Process)” NCT00390221 ↗1“BIIB019 (Daclizumab)” NCT01051349 ↗ |
| Known as | DAC HYP | “150 mg of daclizumab high yield process (DAC HYP) administered subcutaneously (SC)” NCT01143441 ↗ |
| Known as | Daclizumab High Yield Process | “BIIB019 (Daclizumab High Yield Process)” NCT00390221 ↗ |
| Known as | daclizumab, zenapax | “daclizumab, zenapax” NCT00859131 ↗ |
| Known as | DZB | “Specifically, this study is designed to determine the ability of Mycophenolate Mofetil (MMF/CellCept) used alone, or in combination with Daclizumab (DZB/Zenapax) to see if it...” NCT00100178 ↗ |
| Known as | Zenapax | “Specifically, this study is designed to determine the ability of Mycophenolate Mofetil (MMF/CellCept) used alone, or in combination with Daclizumab (DZB/Zenapax) to see if it...” NCT00100178 ↗3“This study will examine the safety and effectiveness of daclizumab (also called Zenapax or anti-CD25) in patients with Wegener's granulomatosis, a type of vasculitis (blood...” NCT00040248 ↗ “This study will examine the safety and effectiveness of daclizumab (also called Zenapax or anti-CD25) in reducing viral replication in patients with HIV infection.” NCT00080431 ↗ “Daclizumab is a humanized anti-Tac monoclonal antibody (HAT, Zenapax)” NCT00001526 ↗ |
| Known as | Zenapax (Daclizumab) | “Zenapax (Daclizumab)” NCT01172418 ↗ |
| Known as | Zenapax(R) | “This protocol is designed to obtain information on the drug levels, metabolism, and safety of daclizumab (Zenapax(R)) in children and adolescents undergoing cardiac transplantation.” NCT00284531 ↗ |
| Action | Inhibit | “Zenapax is a monoclonal antibody that binds to certain proteins (receptors) on white blood cells, preventing them from interacting with a chemical called interleukin-2.” NCT00001865 ↗ |
| Modality | Monoclonal antibody | “humanized anti-Tac monoclonal antibody” NCT00001526 ↗ |
| Route | Intravenous | “intravenous (IV) daclizumab treatments” NCT00001526 ↗ |
| Target | IL2RA | “targeting the high affinity interleukin-2 (IL-2) receptor (IL-2Rα/CD25)” PMID 22383993 ↗ Feb 2012 |